MedPath

Evaluation of Tonabersat for DME

Phase 2
Active, not recruiting
Conditions
Diabetic Macular Edema
Interventions
Other: Placebo
Registration Number
NCT05727891
Lead Sponsor
Jaeb Center for Health Research
Brief Summary

This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.

Detailed Description

The primary objective is to assess the effects of tonabersat, an orally administered Connexin43 hemichannel inhibitor, on central subfield thickness (mean change) compared with placebo in eyes with CI-DME and good visual acuity at 6 months.

Exploratory objectives will evaluate biomarkers of kidney function for potential benefit. Furthermore, this phase 2 study is being conducted to determine whether the conduct of a phase 3 trial has merit and provide information on outcome measures needed to design a phase 3 trial.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
128
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
Tonabersat (80 mg)Tonabersat-
Primary Outcome Measures
NameTimeMethod
Mean change in central subfield thickness6 months
Secondary Outcome Measures
NameTimeMethod
Mean change in retinal volume from baseline6 months
Percentage of eyes central subfield thickness below optical coherence machine- and sex-specific threshold for DME and at least a 10% decrease from baseline6 months

Composite outcome, gender-specific spectral domain optical coherence tomography equivalent of 250 µm on Zeiss Stratus optical coherence tomography

Mean change in visual acuity from baseline6 months
Percentage of eyes receiving other treatment for DME prior to the 6 month visit6 months

Trial Locations

Locations (28)

Retina Associates of Southern California

🇺🇸

Huntington Beach, California, United States

Loma Linda University

🇺🇸

Loma Linda, California, United States

East Bay Retina Consultants, Inc.

🇺🇸

Oakland, California, United States

Southern California Desert Retina Consultants, Inc.

🇺🇸

Palm Desert, California, United States

Macula Retina Vitreous Institute

🇺🇸

Torrance, California, United States

National Ophthalmic Research Institute

🇺🇸

Fort Myers, Florida, United States

University of Florida- Jacksonville

🇺🇸

Jacksonville, Florida, United States

Central Florida Retina Institute

🇺🇸

Lakeland, Florida, United States

Florida Retina Consultants

🇺🇸

Lakeland, Florida, United States

Southeast Eye Institute, P.A. dba Eye Associates of Pinellas

🇺🇸

Pinellas Park, Florida, United States

Scroll for more (18 remaining)
Retina Associates of Southern California
🇺🇸Huntington Beach, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.